BACKGROUND: In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes (PROs) from ALCYONE. METHODS: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaire were administered at baseline, every 3 months (year 1) and every 6 months (until progression). Treatment effects were assessed using a repeated-measures, mixed-effects model. RESULTS: Compliance with PRO assessments was comparable at baseline (> 90%) and throughout study (> 76%) for both treatment groups. Improvements from baseline were observed in both groups for EORTC QLQ-C30 Global Health Status (GHS), most functional scales, symptom scales and EQ-5D-5L visual analog scale (VAS). Between-group differences were significant for GHS (p = 0.0240) and VAS (p = 0.0160) at month 3. Improvements in pain were clinically meaningful in both groups at all assessment time points. Cognitive function declined in both groups, but the magnitude of the decline was not clinically meaningful. CONCLUSIONS: Patients with transplant-ineligible NDMM demonstrated early and continuous improvements in health-related quality of life, including improvements in functioning and symptoms, following treatment with D-VMP or VMP. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02195479 , registered September 21, 2014.

Andrew Love Cancer Centre Geelong Australia

Azienda Ospedaliera Santa Maria Terni Italy

Champalimaud Centre for the Unknown Lisbon Portugal

Clinic of Professional Pathology Saratov Russia

Clinica de Tratamento E Cuiaba Brazil

Clínica Universidad de Navarra Centro de Investigación Médica Aplicada Instituto de Investigación Sanitaria de Navarra Centro de Investigación Biomédica en Red de Cáncer Pamplona Spain

Department of Haematology and Oncology Würzburg University Medical Center Oberdürrbacher Straße 6 97080 Würzburg Germany

Department of Internal Medicine Seoul National University College of Medicine Seoul Republic of Korea

Dnipropetrovsk City Multidisciplinary Clinical Hospital No 4 Dnipropetrovsk Ukraine

Institute of Hematology Department of Experimental Diagnostic and Specialty Medicine University of Bologna Bologna Italy

Janssen Research and Development LLC Spring House PA USA

Janssen Research and Development Raritan NJ USA

Japanese Red Cross Medical Center Tokyo Japan

Leicester Royal Infirmary Leicester UK

LTD Medinvent Institute of Health Tbilisi Georgia

Matsuyama Red Cross Hospital Matsuyama Japan

National and Kapodistrian University of Athens Athens Greece

Semmelweis University Budapest Hungary

Silesian Medical University Katowice Poland

Université Catholique of Louvain CHU UCL Namur Yvoir Belgium

University Hospital Brno Brno Czech Republic

University Hospital of Salamanca Instituto de Investigación Biomédica de Salamanca Salamanca Spain

University Hospitals Birmingham NHS Trust Birmingham UK

University of Chicago Medical Center Chicago IL USA

See more in PubMed

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52–iv61. doi: 10.1093/annonc/mdx096. PubMed DOI

Szabo K, Bodoki L, Nagy-Vincze M, Vincze A, Zilahi E, Szodoray P, Danko K, Griger Z. Effect of genetic and laboratory findings on clinical course of Antisynthetase syndrome in a Hungarian cohort. Biomed Res Int. 2018;2018:6416378. doi: 10.1155/2018/6416378. PubMed DOI PMC

Rodriguez-Otero P, Mateos MV, Martinez-Lopez J, Hernandez MT, Ocio EM, Rosinol L, Martinez R, Teruel AI, Gutierrez NC, Bargay J, et al. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer J. 2019;9(4):36. doi: 10.1038/s41408-019-0176-x. PubMed DOI PMC

Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076–3084. doi: 10.1182/blood-2014-09-568915. PubMed DOI

Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC, Richardson PG. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018;16(8):564–574. PubMed

Djebbari F, Sharpley FA, McLain-Smith S, Vallance G, Eyre TA, Kothari J, Moore S, Ramasamy K. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients. PLoS One. 2020;15(2):e0229469. doi: 10.1371/journal.pone.0229469. PubMed DOI PMC

Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97(5):416–429. doi: 10.1111/ejh.12790. PubMed DOI

Baz R, Lin HM, Hui AM, Harvey RD, Colson K, Gallop K, Swinburn P, Laubach J, Berg D, Richardson P. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015;23(9):2789–2797. doi: 10.1007/s00520-015-2644-6. PubMed DOI

Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol. 2012;89(6):437–457. doi: 10.1111/ejh.12012. PubMed DOI

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528. doi: 10.1056/NEJMoa1714678. PubMed DOI

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365. PubMed DOI

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727–1736. doi: 10.1007/s11136-011-9903-x. PubMed DOI PMC

King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):171–184. doi: 10.1586/erp.11.9. PubMed DOI

Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol. 2011;87(4):330–337. doi: 10.1111/j.1600-0609.2011.01665.x. PubMed DOI

Cocks K, King MT, Velikova G, de Castro GJ, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of Cancer quality of life questionnaire Core 30. Eur J Cancer. 2012;48(11):1713–1721. doi: 10.1016/j.ejca.2012.02.059. PubMed DOI

Cocks K, King MT, Velikova G, Fayers PM, Brown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;44(13):1793–1798. doi: 10.1016/j.ejca.2008.05.008. PubMed DOI

Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of Cancer quality of life questionnaire Core 30. J Clin Oncol. 2011;29(1):89–96. doi: 10.1200/JCO.2010.28.0107. PubMed DOI

Wisløff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J. Measurement of health-related quality of life in multiple myeloma. Nordic myeloma study group. Br J Haematol. 1996;92(3):604–613. doi: 10.1046/j.1365-2141.1996.352889.x. PubMed DOI

Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5(1):70. doi: 10.1186/1477-7525-5-70. PubMed DOI PMC

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. PubMed DOI

Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, Stewart CB, McNatt P, Lockhart K, Anaissie EJ, Barlogie B. Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs. 2011;34(3):219–227. doi: 10.1097/NCC.0b013e3181f9904d. PubMed DOI PMC

Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N. A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol. 2017;99(1):3–17. doi: 10.1111/ejh.12882. PubMed DOI

Myeloma Trialists' Collaborative Group Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113(4):1020–1034. doi: 10.1046/j.1365-2141.2001.02857.x. PubMed DOI

Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37(11):1345–1351. doi: 10.1016/S0959-8049(00)00447-0. PubMed DOI

Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, Groenvold M, Holzner B, Johnson CD, Kemmler G, Tomaszewski KA, Waldmann A, Young TE, Rose M, EORTC Quality of Life Group General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the unites states. Eur J Cancer. 2019;107:153–163. doi: 10.1016/j.ejca.2018.11.024. PubMed DOI

Robinson D Jr, Esseltine DL, Regnault A, Meunier J, Liu K, van de Velde H. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. Br J Haematol. 2016, 174;(3):368–81. 10.1111/bjh.14058. PubMed PMC

Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters S, Davies FE. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. 2014;22(2):417–426. doi: 10.1007/s00520-013-1991-4. PubMed DOI PMC

Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015;100(6):826–833. doi: 10.3324/haematol.2014.120121. PubMed DOI PMC

Delforge M, Dhawan R, Robinson D, Jr, Meunier J, Regnault A, Esseltine DL, Cakana A, van de Velde H, Richardson PG, San Miguel JF. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89(1):16–27. doi: 10.1111/j.1600-0609.2012.01788.x. PubMed DOI

Dimopoulos MA, Palumbo A, Hajek R, Kropff M, Petrucci MT, Lewis P, Millar S, Zhang J, Mei J, Delforge M. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leuk Lymphoma. 2014;55(7):1489–1497. doi: 10.3109/10428194.2013.847933. PubMed DOI PMC

Roussel M, Moreau P, Attal M, Eisenmann JC, Laribi K, Jaccard A, Dib M, Slama B, Chaleteix C, Dorvaux V, Royer B, Frenzel L, Zweegman S, Klein SK, Broijl A, Jie KS, Araujo C, Vanquickelberghe V, de Boer C, Kampfenkel T, Vermeulen J, McKay C, Gries KS, Trudeau J, Sonneveld P. PS1377 improvement in health-related quality of life for newly diagnosed multiple myeloma transplant-eligible patients treated with daratumumab, bortezomib, thalidomide, and dexamethasone: CASSIOPEIA study. HemaSphere. 2019;3(suppl 1):630. doi: 10.1097/01.HS9.0000563784.11014.52. DOI

Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Ramasamy K, Roussel M, Araujo C, Jaccard A, Delforge M, McKay C, Gries K, Trudeau J, Hulin C, Weisel K. Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA. J Clin Oncol. 2019;37(15):8016. doi: 10.1200/JCO.2019.37.15_suppl.8016. DOI

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132–141. doi: 10.1016/S0140-6736(19)32956-3. PubMed DOI

Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–1266. doi: 10.3324/haematol.2014.117176. PubMed DOI PMC

See more in PubMed

ClinicalTrials.gov
NCT02195479